Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHA regimen for relapsed/refractory acute myeloid leukemia
ChiCTR-OPC-14005712Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine, homoharringtonine and cytarabine in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoints: Complete remission rate and Partial remission rate. Started Dec 2014; status: recruiting.
02
Drugs
cladribinehomoharringtoninecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-14005712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-14005712.